The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

frugibio.com

Founded Year

2020

Stage

Acquired | Acquired

About Frugi Biotechnology

Frugi Biotechnology develops paper-based diagnostic solutions to detect pathogens through the use of synthetic biology.On March 28th, 2022, Frugi Biotechnology was acquired by BigHat Biosciences. The terms of the transaction were not disclosed.

Frugi Biotechnology Headquarter Location

2501 N. Loop Drive, Suite 1000

Ames, Iowa, 50010,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Frugi Biotechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Frugi Biotechnology is included in 1 Expert Collection, including Health Monitoring & Diagnostics.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

Latest Frugi Biotechnology News

BigHat Biosciences Completes Its Acquisition of Frugi Biotechnology

Apr 4, 2022

Acquisition to accelerate scaling of BigHat’s AI/ML-enabled drug discovery platform BigHat Biosciences, Inc., a biotechnology company developing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, announced the acquisition of Frugi Biotechnology, a biotechnology company developing cost-effective and high-quality cell-free protein synthesis (CFPS) technology. The terms of the transaction were not disclosed. “We have been enthusiastically watching the progress of BigHat from their launch, and see tremendous potential in the platform they are building; we are honored to join such a world-class team” BigHat plans to integrate this CFPS technology into its novel AI/ML-enabled drug discovery platform to allow BigHat to rapidly scale to meet the growing demands for its platform from partners and for internal therapeutic programs. With this acquisition, BigHat brings in-house a reliable supply of one key input to BigHat’s drug discovery platform. “Cell-free protein synthesis is a foundational technology for BigHat’s platform, allowing us to rapidly synthesize and test antibodies in a matter of days. We are excited to join forces with the incredible team at Frugi to further develop our cell-free synthesis capabilities,” said  Peyton Greenside , BigHat’s CSO and co-founder. Frugi Biotechnology’s proprietary, and scalable CFPS technology will facilitate further research to improve CFPS for antibody production. Adam Carr, Frugi’s co-founder and VP of technology, will join BigHat and continue developing and integrating this technology into BigHat’s platform. “We have been enthusiastically watching the progress of BigHat from their launch, and see tremendous potential in the platform they are building; we are honored to join such a world-class team,” said  Dr. Nigel Reuel  Associate professor at Iowa State University, co-founder and CEO at Frugi Biotechnology.

  • When was Frugi Biotechnology founded?

    Frugi Biotechnology was founded in 2020.

  • Where is Frugi Biotechnology's headquarters?

    Frugi Biotechnology's headquarters is located at 2501 N. Loop Drive, Suite 1000, Ames.

  • What is Frugi Biotechnology's latest funding round?

    Frugi Biotechnology's latest funding round is Acquired.

  • Who are the investors of Frugi Biotechnology?

    Investors of Frugi Biotechnology include BigHat Biosciences and ISU Startup Factory.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.